Bovine Mastitis Market, By Type (Clinical and Sub-Clinical), By Product (Antibiotics and Others), By Route of Administration (Intramammary and Systemic), By Therapy (Lactating Period and Dry Period (Antibiotics and Others)), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) – Global Forecast till 2029

One of the major issues facing the dairy businesses worldwide is bovine mastitis. Every year, the frequency of these occurrences in cattle rises, resulting in significant financial losses for dairy farmers. For example, 31 incidences of clinical mastitis were reported annually in 100 cows in U.S. dairy herds, according to a 2017 research article published in the Journal of Dairy Science. Each case cost between US$ 350 and US$ 500. This covers both direct and indirect expenditures, including labor, future milk production losses, veterinary care, diagnostics, milk loss, and medications, among other things. Compared to indirect losses, direct losses from clinical mastitis are less. In addition, different national and regional estimates place the cost of therapies at between 10% and 12% of the total cost of mastitis in each case. The need for antibiotics in the treatment of the ailment is being driven by the increase in the disease's occurrence in bovine animals as well as the increased awareness among dairy farmers about its treatment. The development of non-antibiotic medications for the treatment of bovine mastitis by market participants has further enhanced this.

Launching Novel Treatment Products to Drive Profitable Market Development. It is expected that new advancements will have a significant effect on this market. The introduction of new goods is presently receiving a lot of attention from veterinary businesses. Companies in the market are forming strategic alliances, mergers, and acquisitions to boost their combined efforts and create new products faster to stop the rising rate of mastitis. For example, Merck & Co., Inc. announced in February 2020 the introduction of Shut Out, a novel intramammary paste that does not include antibiotics and is designed to help prevent intramammary infections, such as mastitis in cattle. It is expected that the launch of these new products will close the clinical gap left by antibiotics and other medications for the effective treatment of mastitis.